RedHill Biopharma (RDHL) Payables (2011 - 2025)

RedHill Biopharma (RDHL) has 15 years of Payables data on file, last reported at $731000.0 in Q4 2025.

• On a quarterly basis, Payables fell 37.41% year-over-year to $731000.0 in Q4 2025; TTM through Dec 2025 was $731000.0, a 37.41% decrease from a year earlier, with the FY2025 full-year figure at $731000.0, down 37.41% from the prior year.
• Payables for Q4 2025 stood at $731000.0, down from $835000.0 in the prior quarter.
• Over the last five years, Payables for RDHL reached as high as $119.4 million in Q4 2022 and fell as low as $731000.0 in Q4 2025.
• Historically, Payables has averaged $13.1 million across 5 years, with a median of $4.4 million in 2022.
• Across the five-year window, Payables jumped 924.06% in 2022 and tumbled 97.26% in 2023, its largest moves.
• Year by year, Payables stood at $11.7 million in 2021, then soared by 924.06% to $119.4 million in 2022, then tumbled by 97.26% to $3.3 million in 2023, then slumped by 64.37% to $1.2 million in 2024, then sank by 37.41% to $731000.0 in 2025.
• Per Business Quant data, the three most recent Payables figures were $731000.0 in Q4 2025, $835000.0 in Q2 2025, and $1.2 million in Q4 2024.